Booming Omics in Schistosoma

Yohann Le Govic (1) , Benjamin Gourbal (2) , Jérôme Boissier (2)

1 GEIHP - Groupe d'Étude des Interactions Hôte-Pathogène
2 IHPE - Interactions Hôtes-Pathogènes-Environnements

Efforts to eliminate schistosomiasis are hindered by incomplete efficacy of the only FDA-approved antischistosomal drug, praziquantel. By using postgenomic technologies, Wendt et al. and Wang et al. deciphered the function of several genes required for worm survival and pathogenesis, which opens the way for the development of innovative parasite-targeted therapies

Mots clés: praziquantel; proteasome; blood feeding; schistosomiasis; RNA interference; scRNA-seq

Domaines: Sciences du Vivant [q-bio]

Yohann Le Govic, Benjamin Gourbal, Jérôme Boissier. Booming Omics in Schistosoma. Trends in Parasitology, 2020, 37 (1), pp.6-8. ⟨10.1016/j.pt.2020.10.010⟩. ⟨hal-03001273⟩